Adlai Nortye Ltd. Announces Topline Results of Phase III Buran Trial Evaluating Buparlisib in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

Adlai Nortye's Phase III BURAN trial of buparlisib (AN2025) in combination with paclitaxel for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) failed to meet its primary endpoint of improving overall survival compared to paclitaxel alone, though the safety profile was consistent with previous findings. The company plans to submit IND applications for AN8025, a PD-1-based immunotherapy, in mid-2025 and for AN9025, an oral small molecule pan-RAS(ON) inhibitor, in the second half of 2025. Preliminary results for AN4005, an orally available PD-L1 inhibitor, showed favorable safety and tolerability with encouraging preliminary efficacy in a tumor type known to respond to anti-PD-(L)1 therapy.

Analysis

Adlai Nortye Ltd. (ANL) reported a significant clinical setback as its Phase III BURAN trial for buparlisib (AN2025), a PI3K inhibitor, combined with paclitaxel, failed to meet the primary endpoint of improving overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) compared to paclitaxel alone. While the safety profile of buparlisib remained consistent with prior studies without new signals, the efficacy failure is a notable event, especially considering the article's remark that these Phase II findings preceded the current standard of care involving anti-PD-(L)1 therapies. Despite this, Adlai Nortye highlighted progress in its earlier-stage pipeline. AN8025, a next-generation tri-specific PD-1-based immunotherapy, has shown enhanced APC quantity and quality, robust T cell activation, and anti-tumor efficacy in preclinical studies, with an Investigational New Drug (IND) application planned for mid-2025. AN9025, an oral pan-RAS(ON) inhibitor, demonstrated potent preclinical efficacy in RAS-mutant cancers such as pancreatic, lung, and colorectal adenocarcinomas, comparing favorably to benchmark agents, with an IND submission expected in the second half of 2025. Furthermore, AN4005, an oral small-molecule PD-L1 inhibitor, showed favorable safety, tolerability, and encouraging preliminary efficacy in advanced tumor patients responsive to anti-PD-(L)1 therapy, as presented at SITC 2024. The overall sentiment is mixed (-0.1), with a slightly negative ticker-specific sentiment for ANL (-0.2), reflecting the Phase III trial disappointment balanced by the potential of its developmental candidates.

Key Decisions for Investors

• Investors should re-evaluate Adlai Nortye's valuation and near-term prospects following the failure of the buparlisib Phase III trial, which was a key late-stage asset.
• Attention should shift to the company's earlier-stage pipeline, particularly monitoring the upcoming IND submissions for AN8025 (mid-2025) and AN9025 (H2 2025), and any subsequent clinical data readouts for these candidates as well as AN4005.
• Consider the increased development risk and longer timelines associated with the now earlier-stage focused pipeline and assess the company's capital runway to support these programs through critical milestones.